genet
test
person
medicin
alreadi
achiev
mani
test
develop
laboratori
provid
healthcar
breakthrough
especi
infecti
diseas
cancer
aid
transform
deadli
diseas
manag
chronic
diseas
larg
part
laboratorydevelop
test
diagnos
manag
hiv
hiv
mutat
rapidli
antivir
drug
hiv
treatment
develop
laboratorydevelop
test
essenti
rapidli
incorpor
new
inform
identifi
drug
use
individu
therapi
allow
treatment
move
one
drug
suit
approach
much
individu
strategi
base
upon
uniqu
genet
natur
individu
diseas
test
develop
lab
also
critic
nation
public
health
defens
allow
identif
sever
acut
respiratori
syndrom
sar
coronaviru
avian
flu
west
nile
viru
although
mani
exampl
exist
underscor
laboratorydevelop
test
abil
respond
rapidli
new
often
menac
health
challeng
continu
allow
within
congression
establish
regulatori
framework
alreadi
exist
laboratori
test
subject
fda
regul
rare
lowvolum
test
genet
diseasessuch
spinal
muscular
atrophi
gaucher
diseas
taysach
diseas
canavan
diseas
among
mani
otherscould
remov
clia
lab
menu
longer
avail
parent
children
afflict
diseas
small
popul
would
avail
clinic
trial
test
wellestablish
medic
import
test
would
abl
meet
fda
requir
andwith
limit
marketscould
disappear
furthermor
fda
preclear
preapprov
laboratorydevelop
test
could
commerci
offer
would
danger
imped
abil
nation
clinic
refer
laboratori
innov
quickli
would
profound
neg
impact
healthcar
deliveri
practic
medicin
would
close
import
public
health
safeti
valv
provid
laboratorydevelop
test
exampl
current
abil
flexibl
variou
laboratori
includ
academ
institut
respond
center
gratifi
howev
editor
share
concern
current
fda
resourc
approach
adequ
meet
larger
challeng
pharmacogenet
support
pew
charit
trust
identifi
mani
regulatori
polici
barrier
imped
effect
translat
scientif
research
clinic
practic
regulatori
landscap
genet
test
believ
need
creativ
nimbl
transpar
scienc
inform
clinic
laboratori
test
advanc
person
medicin
distinguish
individu
like
benefit
particular
drug
dosag
patient
diagnosi
probabl
develop
laboratoryund
feder
oversight
center
medicar
medicaid
servic
clinic
laboratori
improv
amend
clia
test
quickli
modifi
take
advantag
import
new
import
develop
rapidli
advanc
field
medic
scienc
fda
beforemarket
review
laboratorydevelop
test
would
chill
effect
rapid
critic
import
innov
subject
anoth
layer
regul
drive
away
invest
need
valid
incorpor
test
modif
danger
introduc
delay
overlap
fda
regul
best
understood
context
aftermarket
control
essenti
ignor
laboratorydevelop
test
disingenu
talk
let
market
forc
work
play
field
level
editor
surmis
one
genentech
motiv
file
fda
petit
firm
desir
protect
busi
suggest
profit
motiv
suffici
drive
innov
laboratorydevelop
test
somehow
unseemli
industri
player
like
genentech
perspect
analog
situat
counterfeit
drug
one
would
question
right
drug
maker
complain
illeg
copi
sale
fdaapprov
drug
yet
editor
sanction
even
encourag
inhous
copi
sell
diagnost
test
firm
like
genentech
go
great
length
develop
get
approv
market
editori
rightli
point
genentech
primari
state
goal
file
petit
help
ensur
public
safeti
compani
feelsand
center
concurswould
best
serv
treat
highrisk
vitro
diagnost
laboratorydevelop
test
similarli
petit
point
right
feder
agenc
charg
verifi
either
analyt
valid
genet
test
whether
test
actual
find
suppos
clinic
util
relationship
test
result
improv
patient
outcom
editor
question
whether
lack
oversight
harm
one
nt
need
look
far
see
lax
regul
diagnost
test
advers
impact
public
health
quest
diagnost
madison
new
jersey
usa
exampl
recent
notifi
thousand
doctor
patient
might
receiv
inaccur
test
result
compani
problem
test
measur
vitamin
blood
studi
connect
vitamin
defici
condit
rang
bone
weak
heart
attack
high
level
vitamin
toxic
doctor
often
patient
blood
test
recommend
vitamin
supplement
even
quest
highprofil
flub
howev
physician
learn
take
vitamin
test
result
grain
salt
new
york
time
report
year
ago
one
doctor
sent
sampl
blood
six
laboratori
got
result
rang
nanogram
millilit
would
defici
level
nanogramsa
level
three
time
high
consid
adequ
success
patient
respons
epiderm
growth
factor
receptor
egfr
inhibitor
clinic
data
commit
expand
understand
biomark
relationship
diseas
drug
respons
collabor
lead
academ
institut
industri
partner
consist
commit
continu
welcom
genentech
collabor
ongo
effort
demonstr
receptor
genet
variant
predict
respons
monoclon
antibodybas
therapi
rituxan
rituximab
herceptin
trastuzumab
genentech
drug
bodi
knowledg
gener
genentech
mani
clinic
program
would
offer
invalu
insight
genet
variant
affect
drug
respons
ultim
patient
outcom
clinic
data
also
advoc
protect
patient
speak
essenc
person
medicin
guid
patient
toward
best
treatment
subject
may
difficult
toler
unlik
work
fervent
support
vast
potenti
person
medicin
consid
emerg
leader
industrywid
effort
bridg
therapeut
diagnost
therefor
support
polici
may
word
editori
set
field
person
medicin
back
year
tremend
progress
made
bring
precis
diagnos
bettersuit
therapi
patient
costeffect
use
healthcar
dollar
effici
healthcar
system
techniqu
technolog
support
develop
enhanc
biomarkerbas
test
requir
substanti
resourc
includ
signific
financi
invest
order
import
advanc
continu
regulatori
polici
must
creat
appropri
incent
stimul
foster
collabor
environ
believ
genentech
propos
chang
current
regulatori
framework
test
stifl
innov
drive
signific
advanc
patient
healthcar
ceo
clinic
data
newton
massachusett
usa
fulli
support
editori
march
issu
outlin
reason
genentech
south
san
francisco
california
usa
citizen
petit
surrend
vitro
diagnost
us
food
drug
administr
fda
oversight
right
approach
valid
clinic
test
immedi
file
petit
last
decemb
clinic
data
issu
respons
opposit
american
clinic
laboratori
associ
acla
pleas
educ
observ
public
knowledg
industri
group
like
acla
gone
record
object
clinic
data
support
clear
consist
regulatori
polici
endors
degre
regul
necessari
suffici
clinic
data
pgxpredict
genet
biomarkerbas
test
referenc
openli
genentech
petit
develop
accord
current
regulatori
requir
perform
strict
complianc
clinic
laboratori
improv
amendmentsth
rule
test
govern
pgxpredict
test
like
diagnost
test
kind
design
help
predict
patient
respons
certain
therapi
goal
test
improv
patient
outcom
reduc
healthcar
cost
editori
list
valid
reason
fda
intervent
appropri
mean
assur
clinic
util
diagnost
test
addit
clinic
data
believ
industri
whole
fda
alon
make
respons
shift
toward
goal
person
medicin
undoubtedli
must
concert
effort
orchestr
extens
industri
collabor
amass
work
understand
enorm
bodi
molecular
genet
data
role
diseas
simpl
feat
beyond
scope
individu
entiti
editori
illustr
speed
kra
mutat
diagnost
field
develop
relat
emerg
medic
need
enabl
offer
servic
would
never
gener
financi
oper
return
necessari
allow
broad
commerci
introduct
vitro
diagnost
test
kit
condit
mani
case
vitro
diagnost
devic
manufactur
ever
manufactur
kit
test
laboratori
requir
clear
test
fda
mani
test
simpli
would
made
avail
laboratori
offer
present
kit
manufactur
addit
test
broader
applic
also
would
find
difficult
make
way
market
health
human
servic
recent
report
person
medicin
note
ventur
capit
like
remain
primari
sourc
financ
young
innov
space
person
medicin
due
extraordinari
risk
associ
invest
healthcar
technolog
hh
report
goe
suggest
small
chang
regulatori
polici
reimburs
outlook
direct
impact
abil
emerg
firm
attract
necessari
invest
emerg
signific
new
barrier
entri
market
form
new
fda
premarket
requir
accompani
cost
almost
certainli
would
make
difficult
attract
need
invest
result
abil
new
compani
succeed
would
imped
significantli
allow
twentyfirst
centuri
healthcar
revolut
continu
acla
propos
regulatori
model
build
interag
coordin
center
medicar
medicaid
servic
fda
provid
publicli
transpar
test
registri
consist
principl
least
burdensom
regul
fill
identifi
regulatori
gap
avoid
overlap
potenti
conflict
requir
allow
participatori
approach
draw
expertis
industri
stakehold
sincer
hope
new
administr
lead
effort
acceler
person
medicin
commit
regulatori
balanc
allow
remark
scienc
progress
without
place
needless
burden
thought
regul
industri
